Journal
BLOOD
Volume 109, Issue 12, Pages 5160-5163Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2006-12-063594
Keywords
-
Categories
Funding
- NCI NIH HHS [N01 CO12400] Funding Source: Medline
Ask authors/readers for more resources
Clinical studies suggest that treatment with vaccines comprised of idlotype protein may be associated with improved clinical outcome in follicular lymphoma patients. The time-consuming process required to generate patient-specific vaccines is a major limitation, however. Here we report results of a pilot clinical trial with a novel autologous, tumor-derived proteoliposome vaccine formulation that could be rapidly produced within a single day. Vaccination was safe, induced autologous tumor-specific type 1 cytokine responses in 5 out of 10 follicular lymphoma patients, and was associated with induction of a sustained complete response in one patient. Other patients had large tumor burdens and progressed after a median duration of 8 months. These results suggest that further testing of this vaccine formulation, particularly in the setting of minimal disease, is warranted. Furthermore, the proteoliposome formulation may provide a model for vaccine development for other human cancers, for which tumor-associated antigens need not be defined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available